Advertisement

Brain Tumors

  • Jennifer E. Gains
  • Susan C. Short
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Historically radiation oncologists have been cautious about re-irradiating brain tumours because of concerns about the risks of late central nervous system toxicity, especially radionecrosis, which may occur several months to years after treatment. There is, however, a lack of prospective data addressing this approach. Re-irradiation of brain tumours is attracting more interest as our understanding of the tolerance of the brain to radiation evolves, and developments in radiation technology and imaging make highly accurate targeting of biologically relevant tumour volumes possible. With developments in molecular-targeted therapy, further exploration of the role of re-irradiation on its own or in combination with novel agents is needed.

Keywords

High Grade Glioma Stereotactic Radiotherapy Recursive Partitioning Analysis Recurrent Glioma Target Definition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ang K, Jiang GL, Feng Y (2001) Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 50:1013–1020PubMedCrossRefGoogle Scholar
  2. Arcicasa M, Roncadin M, Bidoli E et al (1999) Re-irradiation and lomustine in patients with relapsed high grade gliomas. Int J Radiat Oncol Biol Phys 43:789–793PubMedCrossRefGoogle Scholar
  3. Bobek-Billewicz B, Stasik-Pres G, Majchrzak H (2010) Differentiation between brain tumour recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 48:81–92PubMedGoogle Scholar
  4. Brem H, Piantadosi S, Burger PC et al (1995) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012PubMedCrossRefGoogle Scholar
  5. Carson K, Grossman S, Fisher J (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumour therapy CNS consortium Phase I and Phase II clinical trials. J Clin Oncol 25:2601–2606PubMedCrossRefGoogle Scholar
  6. Chan JL, Lee SW, Fraass BA (2002) Survival and failure patterns of high grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642PubMedCrossRefGoogle Scholar
  7. Chen W (2007) Clinical applications of PET in brain tumours. J Nucl Med 48:1468–1481PubMedCrossRefGoogle Scholar
  8. Cho KH, Hall WA, Gerbi BJ et al (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent gliomas. Int J Radiat Oncol Biol Phys 45:1133–1141PubMedCrossRefGoogle Scholar
  9. Combs SE, Widmer V, Thilman C et al (2005a) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme. Cancer 104:2168–2173PubMedCrossRefGoogle Scholar
  10. Combs SE, Thilmann C, Edler L et al (2005b) Efficacy of fractionated stereotactic re-irradiation in recurrent gliomas: long term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869PubMedCrossRefGoogle Scholar
  11. Combs S, Debus J, Schulz-Ertner D (2007) Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 7:167PubMedCrossRefGoogle Scholar
  12. Combs S, Bischof M, Welzel T (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89:205–210PubMedCrossRefGoogle Scholar
  13. Darakchiev B, Albright R, Breneman J (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236–242PubMedCrossRefGoogle Scholar
  14. Dunkel IJ, Gardner SL, Garvin JH Jr et al (2010) High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neurooncology 12:297–303Google Scholar
  15. Fabrini MG, Perrone F, De Franco L et al (2009) Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. Strahlenther Onkol 185:524–529 (erratum: 703)PubMedCrossRefGoogle Scholar
  16. Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053PubMedCrossRefGoogle Scholar
  17. Fokas E, Wacker U, Gross MW et al (2009) Hypofractionated stereotactic re-irradiation of recurrent glioblastomas: a beneficial treatment option after high dose radiotherapy. Strahlenther Onkol 185:235–240PubMedCrossRefGoogle Scholar
  18. Gabayan AJ, Green SB, Sanan A et al (2006) Gliasite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58:701–709 PubMedCrossRefGoogle Scholar
  19. Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57PubMedCrossRefGoogle Scholar
  20. Grosu A, Weber W, Franz M et al (2005) Re-irradiation of recurrent high grade gliomas using Amino Acid PET (SPECT)/CT/MRI fusion to determine gross tumour volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519CrossRefGoogle Scholar
  21. Gutin P, Iwamoto F, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163PubMedCrossRefGoogle Scholar
  22. Hall EJ, Giaccia AJ (2005) Radiobiology for the radiologist, 6th edn. Lippincott Williams and Wilkins, Philadelphia, PAGoogle Scholar
  23. Hess CF, Schaaf JC, Kortmann RD et al (1994) Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146–149PubMedCrossRefGoogle Scholar
  24. Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 18:1303–1311PubMedGoogle Scholar
  25. Kong DS, Lee JI, Park K et al (2008) Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112:2046–2051PubMedCrossRefGoogle Scholar
  26. Koshi K, Yamamoto H, Nakahara A et al (2007) Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol 82:297–303CrossRefGoogle Scholar
  27. Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumour from radiation injury. J Nucl Med 41:1861–1867PubMedGoogle Scholar
  28. Lederman G, Wronski M, Arbit E (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159PubMedCrossRefGoogle Scholar
  29. Levin VA, Bidaut L, Hou P et al (2010) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. Epub Accessed 15 Apr 2010Google Scholar
  30. Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70:1350–1360PubMedCrossRefGoogle Scholar
  31. Merchant TE, Boop FA, Kun LE et al (2008) A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71:87–97PubMedCrossRefGoogle Scholar
  32. Messahel B, Ashley S, Saran F et al (2009) Relapsed intracranial ependymoma in children in the UK: patterns of relapse, survival and therapeutic outcome. Eur J Cancer 45:1815–1823PubMedCrossRefGoogle Scholar
  33. Milker-Zabel S, Zabel A, Thilmann C et al (2002) Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma. J Neurooncol 60:227–233PubMedCrossRefGoogle Scholar
  34. Nieder C, Adam M, Molls M et al (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60:181–193PubMedCrossRefGoogle Scholar
  35. Nieder C, Astner ST, Mehta MP et al (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31:300–305PubMedCrossRefGoogle Scholar
  36. Patel M, Siddiqui F, Jin J-Y et al (2009) Salvage re-irradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival J Neurooncol 92:185–191PubMedCrossRefGoogle Scholar
  37. Scharfen CO, Sneed PK, Wara WM et al (1992) High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24:583–591PubMedCrossRefGoogle Scholar
  38. Schwer A, Damek D, Kavanagh B et al (2008) A phase I dose escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70:993–1001PubMedCrossRefGoogle Scholar
  39. Shepherd S, Laing R, Cosgrove V et al (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37:393–398PubMedCrossRefGoogle Scholar
  40. Shrieve DC, Alexander E III, Wen PY et al (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275–282PubMedCrossRefGoogle Scholar
  41. Sneed PK, McDermott MW, Gutin PH (1997) Interstitial brachytherapy procedures for brain tumours. Semin Surg Oncol 13:157–166PubMedCrossRefGoogle Scholar
  42. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase II study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRefGoogle Scholar
  43. Tofilon P, Fike J (2000) The radioresponse of the central nervous system: a dynamic process. Radiat Res 153:357–370 PubMedCrossRefGoogle Scholar
  44. Torcuator R, Zuniga R, Mohan YS (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63–68PubMedCrossRefGoogle Scholar
  45. Tselis N, Kolotas C, Birn G et al (2007) CT guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long term results. Strahlenther Onkol 183:563–570PubMedCrossRefGoogle Scholar
  46. Ullrich RT, Kracht LW, Jacobs AH (2008) Neuroimaging in patients with gliomas. Semin Neurol 28:484–494PubMedCrossRefGoogle Scholar
  47. Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regime of temozolomide for recurrent glioblastoma. Neurology 62: 2113–2115PubMedCrossRefGoogle Scholar
  48. Wick W, Steinbach JP, Kuker WM et al (2007) One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma. J Clin Oncol ASCO annual meetings proceedings Part 1 25(18S)Google Scholar
  49. Withers HR (1985) Biological basis for altered fractionation schemes. Cancer 55:2086–2095PubMedCrossRefGoogle Scholar
  50. Wong CS, van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4:273–284PubMedCrossRefGoogle Scholar
  51. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled into Phase II clinical trials. J Clin Oncol 17:2572–2579PubMedGoogle Scholar
  52. Wong E, Huberman M, Lu X-Q (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26:5049Google Scholar
  53. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicentre phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumour Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.University College HospitalLondonUK
  2. 2.UCL Cancer InstituteLondonUK

Personalised recommendations